(Total Views: 370)
Posted On: 02/15/2018 1:37:36 AM
Post# of 72441
Tetraphase’s antibiotic eravacycline, B’s potential competitor, failed Phase 3 and stock dropped 60%.
https://www.fiercebiotech.com/biotech/tetraph...ase-3-flop
https://www.fiercebiotech.com/biotech/tetraph...ase-3-flop
(0)
(0)
Scroll down for more posts ▼
